Clinical trialNCT03338998CompletedPhase 2Interventional

Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

SponsorNovartis PharmaceuticalsEnrollment32Hemorrhagic StrokeIntracerebral Hemorrhage (ICH)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kevin N. Sheth, MD
Yale University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Novartis Investigative Site
Palo Alto, California, United States
Novartis Investigative Site
New Haven, Connecticut, United States
Novartis Investigative Site
Atlanta, Georgia, United States
Novartis Investigative Site
Baltimore, Maryland, United States
Novartis Investigative Site
Detroit, Michigan, United States
Novartis Investigative Site
Cincinnati, Ohio, United States
Novartis Investigative Site
Portland, Oregon, United States
Novartis Investigative Site
Philadelphia, Pennsylvania, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
Charlottesville, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BAF312 solutionBAF312 tabletMatching Placebo for BAF312 solutionMatching Placebo for BAF312 tablet

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Dec 2017
Primary completion: 13 May 2020
Completion: 13 May 2020
Last update posted: 12 Aug 2022
Registered enrollment: 32
Registry id: NCT03338998

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.